Business · 18/12/2023Updated: 10/17/2026 · 1 min read
Pharmacyclics LLC Withdraws FDA Approval for IMBRUVICA Indications for MCL and MZL
Summary
Pharmacyclics LLC has voluntarily withdrawn FDA approval of indications for mantle cell lymphoma and marginal zone lymphoma for IMBRUVICA (ibrutinib) capsules and tablets, citing a request to the FDA.